Vanta Bioscience P/B Ratio
Current P/B Ratio
1.21
Moderate Valuation
Moderate - Reasonably valued relative to book value
Vanta Bioscience (VANTABIO) P/B ratio is 1.21 (Moderate), book value per share ₹6.67 vs Healthcare average P/B of -0.33 — Moderate - Reasonably valued relative to book value. For live price, earnings yield and the full fundamental profile, see Vanta Bioscience stock price NSE.
Current Valuation Metrics
P/B Ratio
1.21
Current Price
₹
Book Value/Share
₹6.67
Exchange
None
Book Value Breakdown (2025)
Balance Sheet Components
Total Equity
₹4 Cr
Share Capital
₹6 Cr
Reserves & Surplus
₹4 Cr
Outstanding Shares
6,000,000
Book Value per Share
₹6.67
Valuation Signal
Signal
Fairly Valued
Sector Context
Sector Average
-0.33
Sector Median
0.63
Sector Rank
#11 of 50
Sector Percentile
22.0%
VANTABIO P/B Ratio — Valuation Insights & Book Value Analysis
Vanta Bioscience price-to-book ratio interpretation, valuation status and historical context — current P/B 1.21 (Moderate). View VANTABIO annual price range for the annual high/low range and current price position.
- Trading at premium to sector average PB of -0.33
VANTABIO vs Healthcare Peers — P/B Ratio Comparison
Vanta Bioscience P/B 1.21 vs Healthcare average -0.33, median 0.63 — range -17.92–1.01.
Sector Average
-0.33
Sector Median
0.63
Lowest P/B
-17.92
Highest P/B
1.01
Companies
50
| Company | Symbol | P/B Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Rekvina Laboratories | VINRKLB | -17.92 | ₹22 | Low |
| Span Divergent | SDL | -6.32 | ₹19 | Low |
| Oxygenta Pharmaceutical | OXYGENTAPH | -5.54 | ₹203 | Low |
| Satiate Agri | SATAGRI | -3.39 | ₹8 | Low |
| Adline Chem Lab | ADLINE | -3.03 | ₹5 | Low |
| Parmax Pharma | PARMAX | -2.48 | ₹14 | Low |
| Bharat Immunologicals | BIBCL | -2.32 | ₹76 | Low |
| Krebs Biochemicals & Ind… | KREBSBIO | -0.71 | ₹127 | Low |
| Cresanto Global | CRESANTO | -0.7 | ₹2 | Low |
| Vivimed Labs | VIVIMEDLAB | -0.63 | ₹53 | Low |